Company Status

Personalized Measurement of Melanoma Malignancy

MLA Diagnostics focuses on developing a prognostic test to improve the care path for patients with cutaneous melanoma. Founded in 2019, MLA Diagnostics B.V. will further develop the patented research from Professor Manon van Engeland. A quantitative methylation specific PCR (Q-MSP) has been developed and we are currently in the process of validating the test in a larger number of patient samples.